文献速递腹部技术与安全MR

CM-101:靶向I型胶原的磁共振成像探针用于检测肝纤维化

CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis.
PubMed 文献 · Radiology · 2017-11-20

本研究在大鼠中测定CM-101的药代动力学与生物分布,并在胆管结扎大鼠及四氯化碳处理小鼠中评估其量化肝纤维化的能力。CM-101血液清除快、主要经肾排泄、骨与组织钆沉积可忽略;注射后肝与肌肉对比噪声比变化在纤维化动物中显著高于对照。

要点

  • CM-101注射后肝-肌肉ΔCNR在纤维化模型中显著升高,可用于量化肝纤维化。
  • CM-101血液半衰期6.8分钟±2.4,主要经肾排泄,24小时组织钆水平低。
  • 骨内钆蓄积可忽略,14天时组织钆水平较24小时低10倍。

核心结论

  • CM-101血液清除快、全身消除完全,骨与组织钆蓄积可忽略,在大鼠胆管结扎模型和小鼠四氯化碳模型中能稳健检测肝纤维化。

研究设计与样本

  • 动物实验:大鼠用于生物分布、药代动力学与稳定性测定(质谱法);胆管结扎与假处理大鼠于术后19天用1.5-T临床磁共振成像设备成像。
  • 小鼠每周两次接受四氯化碳或溶媒处理共10周,用7.0-T临床前磁共振成像设备于基线和末次四氯化碳处理后1周成像。
  • 动物在注射10 µmol/kg CM-101前后成像,以肝与肌肉组织对比噪声比变化(ΔCNR)量化肝纤维化,肝组织行天狼星红染色和羟脯氨酸含量分析。
  • 所有在体操作经机构研究动物护理小组委员会批准。

关键影像表现/征象

  • CM-101注射后肝与肌肉组织ΔCNR在胆管结扎大鼠为13.6±3.2,显著高于假处理大鼠的5.7±4.2(P < .001)。
  • 四氯化碳处理小鼠ΔCNR为18.3±6.5,显著高于基线值5.2±1.0(P < .001)。

诊断标准与关键数值

  • 以注射CM-101后肝与肌肉组织对比噪声比变化(ΔCNR)量化肝纤维化。
  • 胆管结扎大鼠ΔCNR 13.6±3.2 vs 假处理大鼠5.7±4.2,P < .001。
  • 四氯化碳处理小鼠ΔCNR 18.3±6.5 vs 基线5.2±1.0,P < .001。

临床应用与阅片要点

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the biodistribution, metabolism, and pharmacokinetics of a new type I collagen-targeted magnetic resonance (MR) probe, CM-101, and to assess its ability to help quantify liver fibrosis in animal models. Materials and Methods Biodistribution, pharmacokinetics, and stability of CM-101 in rats were measured with mass spectrometry. Bile duct-ligated (BDL) and sham-treated rats were imaged 19 days after the procedure by using a 1.5-T clinical MR imaging unit. Mice were treated with carbon tetrachloride (CCl4) or with vehicle two times a week for 10 weeks and were imaged with a 7.0-T preclinical MR imaging unit at baseline and 1 week after the last CCl4 treatment. Animals were imaged before and after injection of 10 µmol/kg CM-101. Change in contrast-to-noise ratio (ΔCNR) between liver and muscle tissue after CM-101 injection was used to quantify liver fibrosis. Liver tissue was analyzed for Sirius Red staining and hydroxyproline content. The institutional subcommittee for research animal care approved all in vivo procedures. Results CM-101 demonstrated rapid blood clearance (half-life = 6.8 minutes ± 2.4) and predominately renal elimination in rats. Biodistribution showed low tissue gadolinium levels at 24 hours (<3.9% injected dose [ID]/g ± 0.6) and 10-fold lower levels at 14 days (<0.33% ID/g ± 12) after CM-101 injection with negligible accumulation in bone (0.07% ID/g ± 0.02 and 0.010% ID/g ± 0.004 at 1 and 14 days, respectively). ΔCNR was significantly (P < .001) higher in BDL rats (13.6 ± 3.2) than in sham-treated rats (5.7 ± 4.2) and in the CCl4-treated mice (18.3 ± 6.5) compared with baseline values (5.2 ± 1.0). Conclusion CM-101 demonstrated fast blood clearance and whole-body elimination, negligible accumulation of gadolinium in bone or tissue, and robust detection of fibrosis in rat BDL and mouse CCl4 models of liver fibrosis. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Farrar CT, Gale EM, Kennan R, et al. CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis. Radiology. 2017. PMID: 29156148. doi:10.1148/radiol.2017170595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。